Regeneron Pharmaceuticals (MIL:1REGN) EPS (Basic): €36.54 (TTM As of Mar. 2026)


MIL:1REGN Regeneron Pharmaceuticals Inc MIL:1REGN
28 GF Score
Price €540.20
GF Value €786.02
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals EPS (Basic)?

Regeneron Pharmaceuticals MIL:1REGN +2.45% 28 EPS (Basic) is €36.54 as of Mar. 2026. GuruFocus rates MIL:1REGN with a GF Score™ of 28/100 and a GF Value™ of €786.02 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Regeneron Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €6.05. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €36.54.

Regeneron Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was €5.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €35.26.

Regeneron Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was €8.19. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 39.22.

During the past 12 months, Regeneron Pharmaceuticals's average EPS without NRIGrowth Rate was 7.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was -0.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 17.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Regeneron Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 48.40% per year. The lowest was -104.50% per year. And the median was 12.30% per year.

Regeneron Pharmaceuticals  (MIL:1REGN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Regeneron Pharmaceuticals EPS (Basic) Related Terms

Regeneron Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals EPS (Basic) Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.61 38.24 33.98 39.06 36.78

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.01 11.48 12.01 7.01 6.05
MIL:1REGN
28GF Score
Regeneron Pharmaceuticals Inc MIL:1REGN
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Regeneron Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(3847.185-0)/104.600
=36.78

Regeneron Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(629.028-0)/104.000
=6.05

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €36.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €36.54 mean?
Regeneron Pharmaceuticals (MIL:1REGN) has a EPS (Basic) of €36.54 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' EPS (Basic) too high?
Regeneron Pharmaceuticals' current EPS (Basic) is €36.54. Overall, Regeneron Pharmaceuticals has a GF Score™ of 28/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' EPS (Basic) compare to ALNY and RVMD?
Regeneron Pharmaceuticals' EPS (Basic) of €36.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current EPS (Basic) is €36.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (MIL:1REGN) is currently considered Significantly Undervalued. The stock's GF Value™ is €786.02, compared to a current price of €540.20 — trading 31.3% below its estimated fair value. The current EPS (Basic) is €36.54. Regeneron Pharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Regeneron Pharmaceuticals (MIL:1REGN), the current EPS (Basic) is €36.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (MIL:1REGN) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €540.20 is trading 31.3% below its estimated GF Value™ of €786.02. GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for MIL:1REGN:

  • EPS (Basic): €36.54
  • GF Value™: €786.02 vs. price of €540.20 (31.3% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the MIL:1REGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
28GF Score

Get the complete analysis for MIL:1REGN

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€540.20
Price
€786.02
GF Value